112 related articles for article (PubMed ID: 37933549)
1. Long-term organ damage accrual and late mortality in systemic sclerosis.
Lazzaroni MG; Moschetti L; Breda M; Franceschini F; Airò P
Clin Exp Rheumatol; 2023 Oct; ():. PubMed ID: 37933549
[TBL] [Abstract][Full Text] [Related]
2. Anemia Is an Indicator for Worse Organ Damage Trajectories in Patients with Systemic Sclerosis: A Retrospective Study.
Li Z; Xu D; Jiang X; Li T; Su Y; Mu R
J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078943
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
Ferdowsi N; Huq M; Stevens W; Hudson M; Wang M; Tay T; Burchell JL; Mancuso S; Rabusa C; Sundararajan V; Prior D; Proudman SM; Baron M; Nikpour M; ;
Ann Rheum Dis; 2019 Jun; 78(6):807-816. PubMed ID: 30928903
[TBL] [Abstract][Full Text] [Related]
4. Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling.
Barbacki A; Baron M; Wang M; Zhang Y; Stevens W; Sahhar J; Proudman S; Nikpour M; Man A;
Arthritis Care Res (Hoboken); 2023 Mar; 75(3):640-647. PubMed ID: 35226416
[TBL] [Abstract][Full Text] [Related]
5. Anti-Th/To antibodies in systemic sclerosis: analysis of long-term follow-up of pulmonary involvement, organ damage accrual and mortality in an Italian cohort with a case-control study.
Moschetti L; Lazzaroni MG; Cavazzana I; Franceschini F; Airò P
Clin Exp Rheumatol; 2023 Aug; 41(8):1589-1598. PubMed ID: 36762745
[TBL] [Abstract][Full Text] [Related]
6. Cross-sectional study using the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0 (UCLA SCTC GIT 2.0) for gastrointestinal disorders of systemic sclerosis.
Hisada S; Takeuchi S; Tozawa T; Yamada Y; Ito Y; Kodera M
J Dermatol; 2024 Jul; ():. PubMed ID: 38963343
[TBL] [Abstract][Full Text] [Related]
7. Changes in disability and their relationship with skin thickening, in diffuse and limited cutaneous systemic sclerosis: a retrospective cohort study.
Peytrignet S; Manning J; Wragg E; Moore T; Samaranayaka M; Dinsdale G; Herrick AL
Scand J Rheumatol; 2019 May; 48(3):230-234. PubMed ID: 30394164
[TBL] [Abstract][Full Text] [Related]
8. Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.
Zheng B; Wang M; Stevens W; Proudman S; Nikpour M; Baron M; ;
Semin Arthritis Rheum; 2022 Apr; 53():151973. PubMed ID: 35149318
[TBL] [Abstract][Full Text] [Related]
9. Clinical phenotype in scleroderma patients based on autoantibodies.
Santos CS; Morales CM; Castro CÁ; Álvarez ED
Rheumatol Adv Pract; 2023 Apr; 7(Suppl 1):i26-i33. PubMed ID: 36968636
[TBL] [Abstract][Full Text] [Related]
10. Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis.
Lee TH; Lee JS; Park S; Lee KA; Kim HS
Korean J Intern Med; 2021 Nov; 36(6):1504-1514. PubMed ID: 33561335
[TBL] [Abstract][Full Text] [Related]
11. Prediction of damage trajectories in systemic sclerosis using group-based trajectory modelling.
Baron M; Barbacki A; Man A; de Vries-Bouwstra JK; Johnson D; Stevens W; Osman M; Wang M; Zhang Y; Sahhar J; Ngian GS; Proudman S; Nikpour M;
Rheumatology (Oxford); 2023 Sep; 62(9):3059-3066. PubMed ID: 36625513
[TBL] [Abstract][Full Text] [Related]
12. Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database.
Allanore Y; Bozzi S; Terlinden A; Huscher D; Amand C; Soubrane C; Siegert E; Czirják L; Carreira PE; Hachulla E; Zanatta E; Li M; Airò P; Mendoza FA; Rosato E; Distler O;
Arthritis Res Ther; 2020 Oct; 22(1):257. PubMed ID: 33115544
[TBL] [Abstract][Full Text] [Related]
13. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
14. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.
Gualtierotti R; Ingegnoli F; Two R; Meroni PL; Khanna D; Adorni G; Becciolini A; Ciavarella T; Marfia G; Murgo A; Scalone L; Ughi N; Zeni S;
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S55-60. PubMed ID: 26339890
[TBL] [Abstract][Full Text] [Related]
15. Nailfold digital capillaroscopic findings in patients with diffuse and limited cutaneous systemic sclerosis.
Shenavandeh S; Haghighi MY; Nazarinia MA
Reumatologia; 2017; 55(1):15-23. PubMed ID: 28386138
[TBL] [Abstract][Full Text] [Related]
16. Myocardial fibrosis detected by magnetic resonance imaging, elevated U-CRP and higher mRSS are predictors of cardiovascular complications in systemic sclerosis (SSc) patients.
Rodríguez-Reyna TS; Rosales-Uvera SG; Kimura-Hayama E; Hernández-Reyes P; Mercado-Velázquez P; Benavides-Suárez SA; Esquinca-González A; Núñez-Álvarez CA
Semin Arthritis Rheum; 2019 Oct; 49(2):273-278. PubMed ID: 30853116
[TBL] [Abstract][Full Text] [Related]
17. Correction:
Ann Rheum Dis; 2019 Aug; 78(8):e88. PubMed ID: 31296652
[No Abstract] [Full Text] [Related]
18. Differences Sustained Between Diffuse and Limited Forms of Juvenile Systemic Sclerosis in an Expanded International Cohort.
Foeldvari I; Klotsche J; Kasapcopur O; Adrovic A; Terreri MT; Sakamoto AP; Stanevicha V; Sztajnbok F; Anton J; Feldman B; Alexeeva E; Katsicas M; Smith V; Avcin T; Marrani E; Kostik M; Lehman T; Sifuentes-Giraldo WA; Vasquez-Canizares N; Appenzeller S; Janarthanan M; Moll M; Nemcova D; Patwardhan A; Santos MJ; Sawhney S; Schonenberg-Meinema D; Battagliotti C; Berntson L; Bica B; Brunner J; Costa-Reis P; Eleftheriou D; Harel L; Horneff G; Kaiser D; Kallinich T; Lazarevic D; Minden K; Nielsen S; Nuruzzaman F; Uziel Y; Helmus N; Torok KS
Arthritis Care Res (Hoboken); 2022 Oct; 74(10):1575-1584. PubMed ID: 33787070
[TBL] [Abstract][Full Text] [Related]
19. Work disability in scleroderma is greater than in rheumatoid arthritis and is predicted by high HAQ scores.
Ouimet JM; Pope JE; Gutmanis I; Koval J
Open Rheumatol J; 2008; 2():44-52. PubMed ID: 19088871
[TBL] [Abstract][Full Text] [Related]
20. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects.
Diab S; Dostrovsky N; Hudson M; Tatibouet S; Fritzler MJ; Baron M; Khalidi N;
J Rheumatol; 2014 Nov; 41(11):2179-85. PubMed ID: 25274885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
